CG Oncology, Valuation
| CGON Stock | 34.75 0.65 1.91% |
At this time, the firm appears to be undervalued. CG Oncology, Common owns a latest Real Value of USD42.88 per share. The recent price of the firm is USD34.75. Our model approximates the value of CG Oncology, Common from evaluating the firm fundamentals such as Return On Asset of -0.16, shares owned by insiders of 6.95 %, and Price To Book of 4.30 X as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that CG Oncology,'s price fluctuation is very steady at this time. Calculation of the real value of CG Oncology, Common is based on 3 months time horizon. Increasing CG Oncology,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CG Oncology, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CGON Stock. However, CG Oncology,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 34.75 | Real 42.88 | Hype 34.12 |
The intrinsic value of CG Oncology,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence CG Oncology,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of CG Oncology, Common helps investors to forecast how CGON stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CG Oncology, more accurately as focusing exclusively on CG Oncology,'s fundamentals will not take into account other important factors: CG Oncology, Total Value Analysis
CG Oncology, Common is currently estimated to have valuation of 1.77 B with market capitalization of 2.31 B, debt of 461 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the CG Oncology, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.77 B | 2.31 B | 461 K |
CG Oncology, Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CG Oncology, has an asset utilization ratio of 0.1 percent. This suggests that the Company is making USD0.001024 for each dollar of assets. An increasing asset utilization means that CG Oncology, Common is more efficient with each dollar of assets it utilizes for everyday operations.CG Oncology, Ownership Allocation
CG Oncology, Common secures a total of 67.63 Million outstanding shares. The majority of CG Oncology, Common outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in CG Oncology, Common to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in CG Oncology, Common. Please pay attention to any change in the institutional holdings of CG Oncology, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.CG Oncology, Profitability Analysis
The company reported the previous year's revenue of 204 K. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 0.About CG Oncology, Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of CG Oncology, Common. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of CG Oncology, Common based exclusively on its fundamental and basic technical indicators. By analyzing CG Oncology,'s financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of CG Oncology,'s intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of CG Oncology,. We calculate exposure to CG Oncology,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CG Oncology,'s related companies.CG Oncology, Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.3 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.